JW Lifescience Corporation (234080.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	253.7B	257.8B	222.5B	206.9B	188.9B
Cost of Revenue	184.1B	188.1B	165.0B	154.5B	140.8B
Gross Profit	69.6B	69.8B	57.5B	52.4B	48.1B
Operating Expenses
R&D Expense	4.2B	5.5B	4.0B	5.2B	5.7B
SG&A Expense	21.9B	19.2B	10.7B	15.1B	8.8B
General & Admin Expense	1.2B	1.7B	3.5B	2.1B	365.4M
Selling & Marketing Expense	17.7B	17.4B	7.3B	7.5B	8.4B
Other Expenses	11.7B	11.8B	6.9B	1.3B	6.5B
Total Operating Expenses	36.3B	36.5B	21.6B	21.5B	21.0B
Cost and Expenses	220.4B	224.5B	186.6B	176.0B	161.8B
Operating Income (EBIT)	33.3B	33.3B	35.9B	30.9B	27.1B
Non-Operating
Interest Income	2.5B	610.4M	1.5B	1.1B	1.1B
Interest Expense	1.4B	2.8B	2.1B	2.7B	3.1B
Net Interest Income	(1.8B)	(2.2B)	(554.8M)	(1.6B)	(2.0B)
Other Non-Op Income/Expense	(1.4B)	(1.5B)	23.2B	2.8B	(6.3B)
Non-Operating Income (excl Interest)	(1.3B)	(1.3B)	(25.2B)	(4.5B)	(1.7B)
EBT (Pre-Tax Income)	32.0B	31.7B	59.0B	33.7B	20.8B
Income Tax Expense	6.0B	3.1B	15.0B	5.6B	5.8B
Bottom Line
Net Income	26.0B	28.6B	44.0B	28.1B	15.0B
Earnings from Cont. Ops	26.0B	28.6B	44.0B	28.1B	15.0B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	26.0B	28.6B	44.0B	28.1B	15.0B
Per Share
Basic EPS	₩1,681	₩1,847	₩2,843	₩1,818	₩966
Diluted EPS	₩1,681	₩1,847	₩2,843	₩1,818	₩966
Revenue Per Share	₩16,022	₩16,691	₩14,367	₩13,359	₩12,201
Shares
Basic Shares Outstanding	15.8M	15.4M	15.5M	15.5M	15.5M
Diluted Shares Outstanding	15.8M	15.4M	15.5M	15.5M	15.5M
Profitability Metrics
EBITDA	51.8B	51.4B	76.8B	50.8B	43.7B
D&A	18.4B	18.2B	15.7B	15.5B	14.9B
EBIT	33.3B	33.3B	61.1B	35.3B	28.8B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026